« Return to News | CROs/Service Providers | Technology Solutions

Aptiv opens adaptive trial design center

Thursday, April 7, 2011 11:23 AM

Aptiv Solutions, the U.S.-based provider of biopharmaceutical and medical device development services has set up an Adaptive Clinical Trials Innovation Center, according to Pharma Times.

The Innovation Center will work to improve drug development processes through the use of adaptive designs, Aptiv said. According to Reinhard Eisebitt, executive vice president and head of the Innovation Center, Aptiv Solutions is “the only company to combine clinical execution capabilities, statistical and scientific expertise, and a suite of integrated technology to provide clients with a full-service adaptive clinical trial offering.”

Adaptive Clinical Trials Innovation Center will also provide consulting services to pharmaceutical and biotechnology companies, as well as regulatory authorities, on best practices in the field, including assistance with trial design, simulation and execution, development of software tools for adaptive trials, and will work with project teams in clinical operations and data management as well as statistics groups during study conduct.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.